Six skin-booster families now dominate the UK clinic shelf, and choosing between them is more about depth and indication than brand loyalty.
The skin booster category has expanded considerably over the past five years. Where practitioners once had a small number of established hyaluronic acid (HA) products to consider, the shelf now includes bio-remodelling HA formulations, amino-acid and vitamin complexes, and polynucleotide (PN) preparations, each with a distinct mechanism and optimal indication set. This skin booster buying guide is written for licensed UK aesthetic practitioners and clinic owners who need a practical framework for choosing by clinical need rather than familiarity.
What defines a skin booster?
The term "skin booster" has no single regulatory definition in the UK, which partly explains the category confusion. In clinical practice it is used to describe injectable products that improve skin quality at the dermal level rather than adding volume or correcting static lines. The working definition used across most UK training curricula and the British College of Aesthetic Medicine (BCAM) guidance on dermal fillers covers products that hydrate, stimulate collagen synthesis, and improve elasticity through intradermal or subdermal delivery, without the primary aim of volumising tissue.
Most products in this category are non-prescription-only medicines (non-POM) and are therefore legally available to trained non-medical practitioners in England, though not in Wales or Scotland where stricter devolved rules apply. Practitioners should confirm current local requirements before supplying.
The main product families
HA bio-remodelling formulations
These products use high-concentration, thermally or chemically stabilised HA to act as a bio-remodeller rather than a volumiser. The most widely studied example in this class is Profhilo (IBSA Institut Biochimique SA). According to IBSA's manufacturer product information, Profhilo contains 64 mg of HA per 2 ml, combining high-molecular-weight and low-molecular-weight fractions in a hybrid cooperative complex. It is delivered via the BAP (Bio Aesthetic Points) technique and spreads through tissue planes, stimulating multiple collagen and elastin types. It carries a CE mark as a Class III medical device.
Restylane Skinboosters (Galderma) represent a different HA approach: NASHA (Non-Animal Stabilised Hyaluronic Acid) technology delivered via micro-injections using a retrograde technique or a roller needle device. The formulation is a stabilised HA gel designed for superficial to mid-dermal placement. Manufacturer product information from Galderma details two concentrations in the Skinboosters range, Vital and Vital Light, with the latter suited to more superficial placement and thinner skin.
Seventy Hyal 2000 (Sinclair Pharma) uses a non-crosslinked HA at 2,000 kDa molecular weight. According to Sinclair's product documentation, the high molecular weight is intended to maximise skin hydration and provide a foundation layer when used as part of a layered treatment plan. It is delivered via microbolus injection across the face, neck, and decolletage.
Amino-acid and vitamin-complex boosters
Jalupro (Professional Derma) is a solution of free amino acids (glycine, L-proline, L-leucine, and L-lysine) in a water-based carrier. According to manufacturer product information from Professional Derma, the amino acid blend acts as a fibroblast stimulant to increase collagen and elastin synthesis. Jalupro is available in a standard formulation and Jalupro HMW, which adds a high-molecular-weight HA component. It is indicated for skin rejuvenation, photoageing, and post-acne scarring, and is delivered intradermally.
Sunekos (Professional Derma) uses the same amino-acid base as Jalupro but in a patented ratio paired with low-molecular-weight HA. According to Professional Derma's manufacturer information, the Sunekos patent covers the specific 6:1 amino-acid-to-HA ratio intended to activate fibroblast ECM (extracellular matrix) regeneration. Sunekos 200 targets superficial wrinkles and skin quality, while Sunekos 1200 is indicated for deeper tissue laxity with more viscous HA content.
NCTF 135HA (Filorga) is a poly-revitalising solution containing 59 active ingredients including free HA (non-crosslinked), 12 vitamins, 24 amino acids, coenzymes, minerals, and antioxidants. According to Filorga's manufacturer product information, NCTF is delivered via mesotherapy technique (nappage or point-by-point) and is positioned as a global skin revitalisation treatment rather than targeted hydration alone.
Polynucleotides as an adjacent category
Polynucleotide products occupy an adjacent space to skin boosters and merit separate consideration. PNs, such as those available in the polynucleotide range, are extracted from salmon or trout sperm DNA and work via a growth factor receptor mechanism to stimulate fibroblast proliferation and tissue regeneration. The skin booster vs polynucleotide distinction matters clinically: PNs have a stronger evidence base for tissue repair, scarring, and periorbital work, while HA-based boosters lead on acute hydration and bio-remodelling. In practice many clinics sequence the two, but they should not be treated as interchangeable. PNs are also increasingly used post-procedure for accelerated healing rather than as standalone aesthetic treatments.
Choosing by indication
A systematic approach to product selection reduces over-reliance on brand loyalty. The three primary selection criteria are depth of placement, patient skin type and age, and treatment goal.
Skin quality and hydration as the primary goal: HA bio-remodellers (Profhilo, Seventy Hyal 2000, Restylane Skinboosters) are first-line. Profhilo suits mid-to-deep dermal remodelling in patients with established laxity. Restylane Vital Light suits superficial placement in sensitive or thinner skin. Seventy Hyal 2000 works well as a foundational step in a layered protocol.
Fibroblast stimulation and collagen synthesis as the primary goal: Amino-acid complexes (Jalupro, Sunekos) are preferable. Sunekos 1200 is indicated where both laxity and texture are the concern. Jalupro HMW adds HA to the fibroblast-stimulating base when combined hydration and collagen support are needed.
Global revitalisation and dull, fatigued skin: NCTF 135HA's broad nutrient matrix suits this profile. It performs well as a course treatment in the 35 to 50 age group with urban photoageing as the primary presentation.
Periorbital work and scarring: Polynucleotides are the preferred choice for periorbital tissue, post-acne scarring, and post-procedure repair. The mechanism of action via tissue regeneration rather than hydration makes them clinically distinct from conventional skin boosters.
Patient skin tone considerations: Practitioners treating Fitzpatrick IV-VI skin should exercise additional caution with any injectable that carries an inflammatory stimulus, including highly cross-linked HA formulations and PNs, where post-inflammatory hyperpigmentation risk is elevated. No product in this category is contraindicated by skin tone alone, but technique, depth, and post-procedure advice must be adapted.
Comparison table
| Product family | Active ingredient(s) | Mechanism | Best indication | Typical course | Downtime |
|---|---|---|---|---|---|
| Profhilo (IBSA) | 64 mg/2 ml hybrid HA complex (H-HA + L-HA) | Bio-remodelling via BAP technique, stimulates collagen types I, III, IV and elastin | Skin laxity, overall bio-remodelling, ageing skin in patients 35+ | 2 sessions, 4 weeks apart; maintenance every 6 months | Minimal. Small papules resolve within hours. Bruising possible. |
| Restylane Skinboosters (Galderma) | NASHA stabilised HA (20 mg/ml Vital; 12 mg/ml Vital Light) | Intradermal HA hydration, promotes fibroblast activity and collagen stimulation | Fine lines, superficial hydration, perioral area, backs of hands | 3 sessions over 3 months; maintenance every 6 months | Low to moderate. Papules and redness for 12-24 hours. |
| Seventy Hyal 2000 (Sinclair) | Non-crosslinked HA 2,000 kDa | Deep hydration, supports dermal matrix, foundation layer for layered protocols | Skin hydration, dehydrated skin, pre-event treatment | 3 sessions, 2-4 weeks apart | Minimal. Redness and micro-papules settling within hours. |
| Jalupro / Jalupro HMW (Professional Derma) | Free amino acids (glycine, L-proline, L-leucine, L-lysine); HMW adds H-HA | Fibroblast stimulation, ECM collagen and elastin synthesis | Photoageing, post-acne scarring, fine lines, skin texture | 3-4 sessions, 7-10 days apart for induction; monthly maintenance | Low. Erythema and minor swelling 12-24 hours. |
| Sunekos 200 / 1200 (Professional Derma) | Patented amino-acid-to-HA ratio (6:1); Sunekos 1200 uses higher-viscosity HA | Activates fibroblast ECM regeneration via amino-acid-HA complex | 200: superficial wrinkles and skin quality. 1200: deeper laxity and volume support. | 4 sessions, 7 days apart; booster at 3 months | Low. Redness and injection-site papules, typically resolving within 24 hours. |
| NCTF 135HA (Filorga) | 59 actives: non-crosslinked HA, 12 vitamins, 24 amino acids, coenzymes, minerals, antioxidants | Poly-revitalisation via mesotherapy; multi-pathway fibroblast stimulation | Global skin revitalisation, dull or fatigued complexion, urban photoageing | 4-6 sessions, 1-2 weeks apart; monthly maintenance | Low to moderate. Multiple micro-entry points; redness 12-24 hours, bruising possible. |
Combining and sequencing skin boosters
Layered protocols are increasingly common in clinical practice, but practitioners should observe a few practical rules before combining products in the same session or within short intervals.
Profhilo and NCTF are not typically combined in the same session given overlapping tissue distribution and the risk of tissue overloading. Most practitioners sequence them across separate visits separated by at least two weeks. Seventy Hyal 2000 is specifically positioned in several published practitioner protocols as a foundational treatment delivered one session before a bio-remodeller such as Profhilo, to prime the dermal environment.
Polynucleotides can be layered with HA boosters across separate sessions and are commonly used six to eight weeks after a Profhilo course to support ongoing tissue regeneration. The JCAD CMAC guideline on vascular occlusion in HA treatments remains relevant when planning any injectable protocol, including skin boosters: practitioners should confirm their emergency management protocol before starting a new product, even when working in presumed safe tissue planes.
When layering with dermal fillers, skin boosters are typically placed superficially to the filler layer and should be delivered at a separate session to avoid tissue displacement or unintended hydration of the filler material. No manufacturer of the products in this guide endorses same-session placement over or adjacent to existing HA filler without specific guidance in their product information.
Storage and handling
All products in this category are medical devices or injectable preparations requiring controlled storage. General rules across the range include refrigeration at 2-8 degrees Celsius, protection from light, and use before the expiry date on the packaging. Individual requirements are detailed in each manufacturer's product information.
Key handling points applicable to the full range:
- Do not use if the syringe or vial shows any sign of damage, discolouration, or particulate matter.
- Allow the product to reach room temperature for approximately 15 minutes before injection to reduce patient discomfort and ensure consistent flow characteristics.
- Single-use only: never re-cap a used needle or use a partially administered syringe on a second patient.
- Cold chain must be maintained throughout supply. When ordering through a registered pharmacy supplier, confirm the dispatch and packaging method before placing bulk orders.
Buying considerations for a clinic
Clinic owners building a skin booster buying guide UK-relevant framework should consider the following before committing to a stocked range.
Indication breadth vs. depth. A two-product approach (one HA bio-remodeller and one amino-acid stimulator) covers the majority of presentations. Adding NCTF or a polynucleotide preparation extends indication breadth without duplicating mechanisms. Over-stocking multiple HA-only options from different brands creates storage cost and clinical confusion without meaningful patient benefit.
Training and technique. Profhilo's BAP technique, NCTF's mesotherapy delivery, and Sunekos's linear threading approach are distinct. Practitioners should complete product-specific training, ideally endorsed by the manufacturer or a recognised UK aesthetic training provider, before stocking a product.
Regulatory and procurement compliance. All products should be sourced through a GPhC-registered pharmacy or a licensed pharmaceutical wholesaler. Buying from unverified grey-market sources invalidates product liability insurance and places the practitioner in breach of the relevant supply chain regulations. Longeva Pharmacy supplies the full range listed in this guide to UK practitioners with appropriate credentials.
Patient suitability and consent. Every patient requires a clinical consultation, a contraindication screen (pregnancy, autoimmune conditions, allergy to product components, active infection at the proposed treatment site), and written informed consent referencing the specific product being used. Consent cannot be generic to the "skin booster category".
Skin booster brands UK: a practical minimum stock list. For a clinic with moderate patient volume, a reasonable starting stock is: Profhilo (the most widely requested brand by name), one amino-acid stimulator (Sunekos 200 or Jalupro), and one polynucleotide preparation. This three-SKU approach covers bio-remodelling, collagen stimulation, and tissue regeneration without unnecessary duplication.
Key takeaways
- Select by mechanism and indication first: HA bio-remodellers for laxity and hydration, amino-acid complexes for collagen stimulation and photoageing, polynucleotides for repair and periorbital work.
- The skin booster vs polynucleotide distinction is clinically meaningful. Do not treat the categories as interchangeable.
- Sequencing protocols across sessions is preferable to same-session layering for most product combinations.
- Cold chain and single-use rules are non-negotiable across all products in the range.
- Source exclusively from GPhC-registered or licensed wholesaler suppliers to maintain insurance validity and product traceability.
- A three-SKU starting stock (one HA bio-remodeller, one amino-acid stimulator, one PN) covers the majority of clinic indications without over-investment.
- Ensure vascular occlusion emergency protocols are in place before starting any new injectable product, in line with JCAD CMAC guidance.
References
- IBSA Institut Biochimique SA - Profhilo manufacturer product information
- Galderma - Restylane Skinboosters manufacturer product information (available via Galderma UK medical affairs on request)
- Sinclair Pharma - Seventy Hyal 2000 manufacturer product information (available via Sinclair UK on request)
- Professional Derma - Jalupro and Sunekos manufacturer product information (available via Professional Derma UK on request)
- Filorga - NCTF 135HA manufacturer product information (available via Filorga UK on request)
- British College of Aesthetic Medicine (BCAM) - Dermal fillers position statement
- Journal of Clinical Aesthetic Dermatology (JCAD) - CMAC guideline: managing hyaluronic acid vascular occlusion
Reviewed for clinical accuracy under the supervision of our Superintendent Pharmacist, Alicia Barker (GPhC 2241860). Longeva Pharmacy is a GPhC-registered pharmacy (registration 9012378) operating under MHRA WDA(H) licence 59619. Information is intended for licensed UK practitioners and does not replace individual clinical judgement.